07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

Amnestix Inc., Sygnis Pharma deal

Sygnis acquired Amnestix for about €4 million ($5.6 million) in cash and stock. The deal gives Sygnis rights to Amnestix’s genomic discovery platform in CNS and access to projects at the Translational Genomics Research Institute...
07:00 , Jun 9, 2008 |  BioCentury  |  Strategy

Adding shots on goal

A long-standing critique of German biotech companies is that they are too small and rely too much on a single lead program. Two companies last week took steps to change that equation. 4SC AG for...